Abstract
Human-based in vitro hepatic experimental systems are now used routinely in drug development. The initial concept of the use of human-based in vitro systems is based on the known species–species differences in drug properties. Human-specific drug properties, by definition, cannot be defined using nonhuman experimental animals and therefore can be only assessed in the preclinical phase of drug development using in vitro human-based experimental systems such as human hepatocytes. Successful cryopreservation of human hepatocytes greatly enhances the utility of this valuable in vitro experimental system, allowing storage, transport, convenient scheduling of experimentation, and repeat experimentation using hepatocytes isolated from the same donors. Assay procedures with cryopreserved human hepatocytes using multiwell plates for the evaluation of critical drug properties including metabolic stability, drug–drug interaction potential, and drug toxicity during drug development are described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185.
Guengerich, F.P. (2006) Cytochrome P450 s and other enzymes in drug metabolism and toxicity. AAPS J. 8, E101–E111.
Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715.
Fry, J.R. (1982) The metabolism of drugs by isolated hepatocytes. Q. Rev. Drug Metab. Drug Interact. 4, 99–122.
Li, A.P. (2007) Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem. Biol. Interact. 168, 16–29.
Gomez-Lechon, M.J., Castell, J.V., and Donato, M.T. (2007) Hepatocytes – the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem. Biol. Interact. 168, 30–50.
Li, A.P. (2004) In vitro approaches to evaluate ADMET drug properties. Curr. Top. Med. Chem. 4, 701–706.
Li, A.P. (2001) Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today 6, 357–366.
Hewitt, N.J., Lechon, M.J., Houston, J.B., Hallifax, D., Brown, H.S., Maurel, P., Kenna, J.G., Gustavsson, L., Lohmann, C., Skonberg, C., Guillouzo, A., Tuschl, G., Li, A.P., LeCluyse, E., Groothuis, G.M., and Hengstler, J.G. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39, 159–234.
Loretz, L.J., Li, A.P., Flye, M.W., and Wilson, A.G. (1989) Optimization of cryopreservation procedures for rat and human hepatocytes. Xenobiotica 19, 489–498.
Li, A.P., Lu, C., Brent, J.A., Pham, C., Fackett, A., Ruegg, C.E., and Silber, P.M. (1999b) Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. Chem. Biol. Interact. 121, 17–35.
Li, A.P., Gorycki, P.D., Hengstler, J.G., Kedderis, G.L., Koebe, H.G., Rahmani, R., de Sousas, G., Silva, J.M., and Skett, P. (1999a) Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem. Biol. Interact. 121, 117–123.
Jouin, D., Blanchard, N., Alexandre, E., Delobel, F., David-Pierson, P., Lavé, T., Jaeck, D., Richert, L., and Coassolo, P. (2006) Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. Eur. J. Pharm. Biopharm. 63, 347–355.
Brown, H.S., Griffin, M., and Houston, J.B. (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab. Dispos. 35, 293–301.
Kafert-Kasting, S., Alexandrova, K., Barthold, M., Laube, B., Friedrich, G., Arseniev, L., and Hengstler, J.G. (2006) Enzyme induction in cryopreserved human hepatocyte cultures. Toxicology 220, 117–125.
Bi, Y.A., Kazolias, D., and Duignan, D.B. (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos. 34, 1658–1665.
Lavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R.C., Jaeck, D., and Coassolo, P. (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. 14, 152–155.
Lu, C., Li, P., Gallegos, R., Uttamsingh, V., Xia, C.Q., Miwa, G.T., Balani, S.K., and Gan, L.S. (2006) Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab. Dispos. 34, 1600–1605.
Lee, K., Vandenberghe, Y., Herin, M., Cavalier, R., Beck, D., Li, A., Verbeke, N., Lesne, M., and Roba, J. (1994) Comparative metabolism of SC-42867 and SC-51089, two PGE2 antagonists, in rat and human hepatocyte cultures. Xenobiotica 24, 25–36.
Zhang, D., Wang, L., Raghavan, N., Zhang, H., Li, W., Cheng, P.T., Yao, M., Zhang, L., Zhu, M., Bonacorsi, S., Yeola, S., Mitroka, J., Hariharan, N., Hosagrahara, V., Chandrasena, G., Shyu, W.C., and Humphreys, W.G. (2007) Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Drug Metab. Dispos. 35, 150–167.
FDA. (2006) Drug interaction studies―study design, data analysis, and implications for dosing and labeling. Available at: http://www.fda.gov/cder/guidance/2635fnl.pdf.
Li, A.P. (2009) Metabolism comparative cytotoxicity assay (MCCA) and cytotoxic metabolic pathway identification assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1. Chem. Biol. Interact. 179, 4–8.
Li, A.P., Bode, C., and Sakai, Y. (2004) A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCR-7 adenocarcinoma breast cancer cells. Chem. Biol. Interact. 150, 129–136.
Li, A.P. (2008) In vitro evaluation of human xenobiotic toxicity: scientific concepts and the novel integrated discrete multiple cell co-culture (IdMOC) technology. ALTEX 25, 4F–49.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Li, A.P. (2010). Evaluation of Drug Metabolism, Drug–Drug Interactions, and In Vitro Hepatotoxicity with Cryopreserved Human Hepatocytes. In: Maurel, P. (eds) Hepatocytes. Methods in Molecular Biology, vol 640. Humana Press. https://doi.org/10.1007/978-1-60761-688-7_15
Download citation
DOI: https://doi.org/10.1007/978-1-60761-688-7_15
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-687-0
Online ISBN: 978-1-60761-688-7
eBook Packages: Springer Protocols